MCOLN1 and mucolipidosis type IV: Other small molecule agonists of TRMPL1, such as SF-22 and MK6-83, have also been developed and successfully used to restore TRPML1 activity and rescue disease-associated abnormalities in fibroblasts from MLIV patients (Table 1) [83,84].